Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry

201746 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier, NCT00799877.

Good health and well-being

Published in: Dermatology and Therapy

Volume 7, Issue 3, pp. 365-381

Field-Weighted Citation Impact: 2.01